MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

94.51
-0.06
-0.06%
Pre Market: 97.00 +2.49 +2.63% 09:19 08/06 EDT
OPEN
94.26
PREV CLOSE
94.57
HIGH
95.23
LOW
92.00
VOLUME
3.58K
TURNOVER
--
52 WEEK HIGH
97.82
52 WEEK LOW
32.30
MARKET CAP
6.63B
P/E (TTM)
202.33
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRSP stock price target is 95.21 with a high estimate of 140.00 and a low estimate of 31.00.

EPS

CRSP News

More
How Vertex Pharmaceuticals Wowed With Its Q2 Results
MotleyFool.com · 6d ago
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior ma
GlobeNewswire · 07/30 12:00
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24
Crispr Therapeutics Down 4% On Earnings Miss; Street Stays Bullish
Shares in Crispr Therapeutics (CRSP) fell 4% in Monday’s after-hours trading, after the gene-focused biopharma reported disappointing second quarter earning results.Specifically, second quarter GAAP EPS of -$1.30 fell short of Street estimates by $0.39 while c
SmarterAnalyst · 07/28 07:53
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -41.30% and -99.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/27 22:15
Crisper Therapeutics shares decline on wider-than-expected loss
Crisper Therapeutics AG shares declined in the extended session Monday after the gene-editing company reported a wider-than-expected loss. Crisper shares declined 2.3% after hours, following a 2% rise in the regular session to close at $92.12. The company rep
MarketWatch · 07/27 21:01
CRISPR Therapeutics EPS misses by $0.39, misses on revenue
Seeking Alpha · 07/27 20:34
CRISPR Therapeutics Q2 Net Loss $79.7M vs Net Loss $53.7M In Same Qtr. Last Year, Sales $100K vs $300K Year Over Year
Benzinga · 07/27 20:31

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About CRSP

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.
More

Webull offers kinds of Crispr Therapeutics AG stock information, including NASDAQ:CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.